{
    "clinical_study": {
        "@rank": "6624", 
        "arm_group": [
            {
                "arm_group_label": "HS-410 Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "HS-410 given as 1*10^6 cells for 12 weekly injections followed by 3 monthly injections open label in Phase 1 portion"
            }, 
            {
                "arm_group_label": "HS-410 High-Dose", 
                "arm_group_type": "Experimental", 
                "description": "HS-410 given as 1*10^7 cells for 12 weekly injections followed by 3 monthly injections open label in the Phase 1 portion"
            }, 
            {
                "arm_group_label": "HS-410 Phase 2 dose", 
                "arm_group_type": "Experimental", 
                "description": "Optimal dose of HS-410 from Phase 1 given as 12 weekly injections followed by 3 monthly injections randomized double-blind"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given as 12 weekly injections followed by 3 monthly injections randomized double-blind"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two-part study.  The first stage will test the safety of HS-410 and the second\n      stage will determine whether vaccination with HS-410 after transurethral resection of\n      bladder tumor (TURBT) and bacillus Calmette-Gu\u00e9rin (BCG) extends the time to disease\n      recurrence compared to placebo."
        }, 
        "brief_title": "A Phase 1/2 Study of HS-410 in Patients With High-Risk Non-Muscle Invasive Bladder Cancer After TURBT and BCG", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed or recurrent high grade non-muscle invasive bladder cancer with or\n             without carcinoma in situ that has been removed by transurethral resection\n\n          -  Received 3-6 weekly doses of intravesical bacillus Calmette-Gu\u00e9rin (BCG) in the\n             adjuvant setting\n\n          -  Adequate laboratory parameters\n\n          -  Bladder cancer risk assessment score >=8 on the recurrence scale and <=18 on the\n             progression scale\n\n        Exclusion Criteria:\n\n          -  Prior immunologic or biologic response modifier therapy for treatment of this\n             occurrence\n\n          -  Recurrence <12 months from most recent prior transurethral resection of bladder tumor\n             (TURBT)\n\n          -  Prior immunologic, biologic response modifier, chemotherapy, radiation, or  therapy\n             for treatment of this occurrence\n\n          -  Intercurrent autoimmunity or immunodeficiency syndromes\n\n          -  Significant cardiac impairment\n\n          -  Other malignancies within the last 3 years\n\n          -  Known allergy to soy or egg products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "93", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010203", 
            "org_study_id": "HS410-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HS-410 Low Dose", 
                    "HS-410 High-Dose", 
                    "HS-410 Phase 2 dose"
                ], 
                "description": "Vaccine derived from irradiated urothelial bladder cancer cells genetically engineered to continually secrete gp96", 
                "intervention_name": "HS-410", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Injection containing sterile solution but no cells", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "TURBT", 
            "Bladder", 
            "Cancer", 
            "GP96", 
            "Vaccine", 
            "Immunotherapy", 
            "Heat Biologics", 
            "BCG", 
            "Bacillus Calmette-Guerin"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jgibson@tucc.com", 
                    "last_name": "Judy Gibson", 
                    "phone": "303-421-5783"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80211"
                    }, 
                    "name": "Urology Center of Colorado"
                }, 
                "investigator": {
                    "last_name": "Larry Karsh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mschroder@surgery.bsd.uchicago.edu", 
                    "last_name": "MaryAnn Schroder", 
                    "phone": "773-834-9198"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Gary Steinberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cdallas@1sturology.com", 
                    "last_name": "Christina Dallas", 
                    "phone": "812-288-2611"
                }, 
                "facility": {
                    "address": {
                        "city": "Jeffersonville", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47130"
                    }, 
                    "name": "First Urology"
                }, 
                "investigator": {
                    "last_name": "James Bailen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "madeline_carroll@med.unc.edu", 
                    "last_name": "Madeline Carroll", 
                    "phone": "919-843-5199"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina Chapell Hill"
                }, 
                "investigator": {
                    "last_name": "Michael Woods, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michelle Allen", 
                    "phone": "843-449-1010", 
                    "phone_ext": "265"
                }, 
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29572"
                    }, 
                    "name": "Carolina Urologic Research Center"
                }, 
                "investigator": {
                    "last_name": "Neal Shore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With High-Risk Non-Muscle Invasive Bladder Cancer Who Have Undergone TURBT and Received Prior Treatment With Induction BCG", 
        "other_outcome": [
            {
                "description": "Evaluation of pre-treatment tumor tissue for antigen expression", 
                "measure": "Tumor antigen expression analysis", 
                "safety_issue": "No", 
                "time_frame": "At screening"
            }, 
            {
                "description": "Evaluation of post-treatment tumor tissue for the presence of infiltrating T-cells", 
                "measure": "Tumor Infiltrating Lymphocytes (TILs)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }
        ], 
        "overall_contact": {
            "email": "mprice@heatbio.com", 
            "last_name": "Melissa Price, PhD", 
            "phone": "919-240-7133"
        }, 
        "overall_contact_backup": {
            "email": "jkelley@heatbio.com", 
            "last_name": "Jennifer Kelley", 
            "phone": "919-240-7133"
        }, 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "Gary Steinberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Immunologic response via intracellular cytokine staining (ICS) by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) on CD8+ cells after receiving 6 vaccine doses.", 
                "measure": "Phase 1: Immune response", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Phase 2: Time to Recurrence", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010203"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Heat Biologics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Heat Biologics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}